质子与光子乳房切除术后放疗对乳房重建结局及剂量学的影响
本研究回顾性分析了2011至2022年在本机构接受乳房切除术后放疗的203例乳房重建患者,其中质子组50例(25%),光子组153例(75%),中位随访4.7年。质子放疗组包膜挛缩(30% vs 10%;OR 3.9;P<.001)和总体重建失败(56% vs 36%;OR 2.2;P=.01)发生率显著高于光子组,而感染/坏死和绝对重建失败无显著差异。质子组剂量学参数与并发症无显著相关性,5年局部失败累积发生率两组无显著差异(0% vs 4%;P=.13)。
要点
- 质子乳房切除术后放疗组包膜挛缩发生率30%,光子组10%(OR 3.9;P<.001)。
- 质子组总体重建失败率56%,光子组36%(OR 2.2;P=.01),差异显著。
- 质子组剂量学参数与重建并发症无显著相关性,5年局部失败两组无显著差异。
核心结论
- 质子乳房切除术后放疗与光子放疗相比,植入物包膜挛缩和重建失败率更高,但局部控制率相当。
研究设计与样本
- 回顾性分析2011年至2022年在本机构接受乳房切除术后放疗的乳腺癌患者记录,共203例,按治疗方式分为质子组50例(25%)和光子组153例(75%),中位随访4.7年。
主要发现
- 质子组与光子组感染/坏死发生率分别为20%和13%(OR 1.6;P=.2),差异无统计学意义。
- 质子组与光子组包膜挛缩发生率分别为30%和10%(OR 3.9;P<.001),差异有统计学意义。
- 质子组与光子组绝对重建失败率分别为16%和12%(OR 1.4;P=.4),差异无统计学意义。
- 质子组与光子组总体重建失败率分别为56%和36%(OR 2.2;P=.01),差异有统计学意义。
- 质子组与光子组5年局部失败累积发生率分别为0%和4%(P=.13),差异无统计学意义。
关键数值与推荐
- 质子组临床靶区、植入物和皮肤的中位平均剂量分别为50.6、50.8和6.7 Gy(RBE)。
- 质子组临床靶区、植入物和皮肤的中位热点剂量(D1cc)分别为52.8、52.7和49.8 Gy(RBE)。
- 上述剂量学参数均与并发症无显著相关性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the impact of proton versus photon postmastectomy radiation therapy (PMRT) on implant-related complications. METHODS AND MATERIALS: The records of patients with breast cancer treated with mastectomy and expander and/or implant reconstruction followed by PMRT at our institution between 2011 and 2022 were reviewed. Patients were divided into 2 groups by treatment modality: proton and photon groups. All identified patients in the proton group were treated using conventional fractionation, and radiobiological effectiveness (RBE) was scaled to 1.1. Recorded complications included infection/skin necrosis requiring operative debridement, capsular contracture necessitating capsulotomy, absolute reconstruction failure implying complete loss of reconstruction, and overall reconstruction failure defined as multiple revisions leading to replacement of the implant or salvage autologous reconstruction. Subgroup analysis for patients in the proton group explored the correlation between dosimetric parameters and complications. Logistic regression and Cox proportional hazards regression models were used. RESULTS: A total of 203 patients with an overall median follow-up of 4.7 years were identified. Among those 203 patients, 50 patients (25%) received proton PMRT, while 153 patients (75%) received photon PMRT. The complication rates for proton versus photon therapies were infection/necrosis (20% vs 13%; OR, 1.6; P = .2), capsular contracture (30% vs 10%; OR, 3.9; P < .001), absolute reconstruction failure (16% vs 12%; OR, 1.4; P = .4), and overall reconstruction failure (56% vs 36%; OR, 2.2; P = .01). Sensitivity analyses and time-to-event models yielded similar results. The median (Dmean) for clinical target volume, implant, and skin was 50.6, 50.8, and 6.7 Gy (RBE), respectively. The median hot spot (D1cc) for clinical target volume, implant, and skin was 52.8, 52.7, and 49.8 Gy (RBE), respectively. None of these parameters were significantly correlated with complications. The 5-year local failure cumulative incidence was 0% versus 4% (P = .13) for proton and photon cohorts, respectively. CONCLUSIONS: Proton PMRT was associated with higher rates of implant capsular contracture and reconstruction failures than photon PMRT with comparable local control. No dosimetric parameter correlated with reconstruction complications.
引用
- Naoum GE, Dobinda K, Yalamanchili A, et al. Protons Versus Photons Postmastectomy Radiation Therapy Effects on Breast Reconstruction Outcomes and Dosimetry Analysis. Int J Radiat Oncol Biol Phys. 2025. PMID: 39947259. doi:10.1016/j.ijrobp.2025.01.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。